Korean J Gastroenterol.  2019 Dec;74(6):301-303. 10.4166/kjg.2019.74.6.301.

Asian Physician's Perspectives on Biosimilars in Inflammatory Bowel Disease: Are We Ready to Use?

• Na SY

• KMID: 2469903
• DOI: http://doi.org/10.4166/kjg.2019.74.6.301

Abstract

No abstract available.

MeSH Terms

Asian Continental Ancestry Group*
Biosimilar Pharmaceuticals*
Humans
Inflammatory Bowel Diseases*
Biosimilar Pharmaceuticals

Reference

1. Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn's and colitis epidemiology study. Gastroenterology. 2013; 145:158–165.e2.

2. Kim JW, Lee CK, Lee JK, et al. Long-term evolution of direct healthcare costs for inflammatory bowel diseases: a population-based study (2006–2015). Scand J Gastroenterol. 2019; 54:419–426.

3. Ebbers HC, Crow SA, Vulto AG, Schellekens H. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol. 2012; 30:1186–1190.

4. Biosimilars of infliximab. [Internet]. Mol: Generics and Biosimilars Initiative;updated 2019 Nov 29. cited 2019 Nov 30. Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-of-infliximab.

5. Biosimilars of adalimumab. [Internet]. Mol: Generics and Biosimilars Initiative;updated 2019 Nov 15. cited 2019 Nov 30. Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-of-adalimumab.

6. Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin Immunol. 2013; 149:534–555.

7. Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018; 78:463–478.

8. Ebada MA, Elmatboly AM, Ali AS, et al. An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease. Int J Colorectal Dis. 2019; 34:1633–1652.

9. Milassin Á, Fábián A, Molnár T. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Therap Adv Gastroenterol. 2019; 12:1756284819842748.

10. Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. J Crohns Colitis. 2017; 11:26–34.

11. Lamb CA, Kennedy NA, Raine T, et al. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019; 68:Suppl 3. s1–s106.

12. Ooi CJ, Hilmi I, Banerjee R, et al. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. J Gastroenterol Hepatol. 2019; 34:1296–1315.

13. Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. J Crohns Colitis. 2014; 8:1548–1550.

14. Danese S, Fiorino G, Michetti P. Changes in biosimilar knowledge among European Crohn's Colitis Organization [ECCO] members: an updated survey. J Crohns Colitis. 2016; 10:1362–1365.

15. Park SK, Moon W, Kim ES, Park SH, Park DI. Knowledge and viewpoints on biosimilar monoclonal antibodies among Asian physicians: comparison with European physicians. Korean J Gastroenterol. 2019; 74:333–340.